Pharmacyte Biotech Inc (OTCMKTS:PMCB) Pushes Up, Pumps Resurface

In yesterday’s session Pharmacyte Biotech Inc (OTCMKTS:PMCB) shuffled up once more and managed to close just over $0.12 per share. Share volume was well above the monthly average, at 4.4 million shares traded over the course of the session.

The company has been increasingly active on the press release front, with a bunch of releases in the two short weeks of the new month so far. On October 9 the company reminded the public it had secured an orphan drug designation by the US FDA back in late 2014 and now “it seems”, in the PR’s own words, that PMCB will get orphan designation from the European Medicines Agency (EMA).

The orphan designation for a drug or treatment provides a 10-year marketing exclusivity period in Europe, and a 7-year period in the USA.

Only yesterday the company announced that it is preparing a clinical trial to “meet critical unmet” need among pancreatic cancer patients. The trial seeks to find an alternative to what is referred to as the “gold standard” in pancreatic cancer treatment.

With PMCB making some good progress up the chart from its lowest close for the past 52-weeks at $0.072 last month, it seems promoters saw it fit to send out a new round of emails. There are two recent paid pump mails for PMCB coming on Oct 8 and Oct 11, compensated with $18 thousand and $14 thousand respectively. One of the promoters is a familiar name – OTC Journal, run by Mr. Larry Isen. A quick Google search can shed some more light on why this is not the best name to see associated with a stock you’re looking at, even if it’s collateral association through a third-party compensated promotion.

As we have said before, PMCB has the looks of a serious company about it, and one that is run by a competent medical team who maintain a close relationship with many established medical institutions all over the world. In this sense, it’s all the more disturbing that PMCB is among the most heavily promoted stocks of 2015, with over 160 pump emails coming in the current year. While the company announced retaining the services of BUYINS dot NET, who will “monitor the market makers” of PMCB stock for compliance, there’s still no official word on the dozens and dozens of promotional emails.